Logo IMG
HOME > My Amsci > Restricted Access

Restricted Access The content you've requested is available without charge only to active Sigma Xi members and American Scientist subscribers.

If you are an active member or an individual subscriber, please log in now in order to access this article.

If you are not a member or individual subscriber, you can:


2010-07ReaF1.jpgClick to Enlarge ImageMost pet owners are aware of the “deworming” medication that prevents heart worm, but few know that ivermectin also prevents or cures onchocerciasis in human beings. River blindness, as it is commonly known, is endemic to 34 nations, most of them in Africa, and affects 37 million people. 500,000 of those are already experiencing severe visual impairment, and 300,000 are blind. The authors describe ivermectin's development and pharmacology, and tell the story of how a few persistent individuals at Merck & Co. arranged to have it provided for free to those who cannot afford it, allaying untold misery in the developing world.

Connect With Us:


Subscribe to Free eNewsletters!

Read Past Issues on JSTOR

JSTOR, the online academic archive, contains complete back issues of American Scientist from 1913 (known then as the Sigma Xi Quarterly) through 2005.

The table of contents for each issue is freely available to all users; those with institutional access can read each complete issue.

View the full collection here.

RSS Feed Subscription

Receive notification when new content is posted from the entire website, or choose from the customized feeds available.

Write for American Scientist

Review our submission guidelines.

Subscribe to American Scientist